标题
Genetic alterations and their clinical implications in DLBCL
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-24
DOI
10.1038/s41571-019-0225-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
- (2019) Stephen M. Ansell et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
- (2019) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
- (2018) Craig S. Sauter et al. BLOOD
- An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma
- (2018) John M. Burke et al. Clinical Lymphoma Myeloma & Leukemia
- Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B Cell Lymphoma, Leg Type
- (2018) Xiaolong Alan Zhou et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- A multiprotein supercomplex controlling oncogenic signalling in lymphoma
- (2018) James D. Phelan et al. NATURE
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- (2018) Bjoern Chapuy et al. NATURE MEDICINE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
- (2018) Xiaoxiao Wang et al. NEOPLASIA
- Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
- (2018) S de Vos et al. ANNALS OF ONCOLOGY
- An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
- (2018) Franck Morschhauser et al. BLOOD
- Phase Ib trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma
- (2018) Christian Grommes et al. BLOOD
- NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
- (2018) Yuxuan Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
- (2017) Vincent Ribrag et al. HAEMATOLOGICA
- CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
- (2017) Yasuhiro Oki et al. HAEMATOLOGICA
- TP53 mutation and survival in aggressive B cell lymphoma
- (2017) Thorsten Zenz et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma
- (2017) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2017) Catherine Thieblemont et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
- (2017) Darius Juskevicius et al. Journal of Hematology & Oncology
- MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R
- (2017) Catherine Lai et al. LEUKEMIA & LYMPHOMA
- Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma
- (2017) Andrés E Quesada et al. MODERN PATHOLOGY
- Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors
- (2017) Sarah J. Horton et al. NATURE CELL BIOLOGY
- Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma
- (2017) Mei Zheng et al. NEUROPATHOLOGY
- Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth
- (2017) Hind Hashwah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma
- (2017) Jiyuan Zhang et al. Cancer Discovery
- Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
- (2017) Christian Grommes et al. Cancer Discovery
- Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum
- (2017) Danielle M. Greenawalt et al. Oncotarget
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
- (2017) Vincent Ribrag et al. HAEMATOLOGICA
- CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
- (2017) Yasuhiro Oki et al. HAEMATOLOGICA
- Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
- (2017) Andrés J M Ferreri et al. Lancet Haematology
- Genomic characterization of primary central nervous system lymphoma
- (2016) Kazutaka Fukumura et al. ACTA NEUROPATHOLOGICA
- Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma
- (2016) Kohei Taniguchi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
- (2016) P. M. Barr et al. BLOOD
- Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
- (2016) S. E. Assouline et al. BLOOD
- Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
- (2016) K. Georgiou et al. BLOOD
- Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group
- (2016) Alejandro Martín et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sole rearrangement but not amplification ofMYCis associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable
- (2016) Daniel J. Landsburg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
- (2016) Felicitas Hitz et al. BRITISH JOURNAL OF HAEMATOLOGY
- Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma
- (2016) Yago Nieto et al. CANCER
- Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
- (2016) Michael Boice et al. CELL
- Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
- (2016) Z. Y. Xu-Monette et al. CLINICAL CANCER RESEARCH
- Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
- (2016) Sydney Dubois et al. CLINICAL CANCER RESEARCH
- MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
- (2016) J. Rovira et al. CLINICAL CANCER RESEARCH
- Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study
- (2016) S. Dubois et al. CLINICAL CANCER RESEARCH
- A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- (2016) Ian W. Flinn et al. EUROPEAN JOURNAL OF CANCER
- ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
- (2016) Grzegorz S Nowakowski et al. Future Oncology
- Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
- (2016) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma
- (2016) N M Reddy et al. LEUKEMIA
- P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma
- (2016) Xuan J Wang et al. MODERN PATHOLOGY
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
- (2016) Yanwen Jiang et al. Cancer Discovery
- Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
- (2016) Thomas Melchardt et al. Oncotarget
- Diffuse large B-cell lymphoma: R-CHOP failure--what to do?
- (2016) B. Coiffier et al. Hematology-American Society of Hematology Education Program
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial
- (2016) Patrick B Johnston et al. Lancet Haematology
- Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas
- (2015) Yago Nieto et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Targetable genetic features of primary testicular and primary central nervous system lymphomas
- (2015) B. Chapuy et al. BLOOD
- MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
- (2015) C. Copie-Bergman et al. BLOOD
- Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
- (2015) F. Offner et al. BLOOD
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
- (2015) Yasuhiro Oki et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study
- (2015) Timothy S. Fenske et al. CANCER
- Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
- (2015) Xi Wang et al. CELLULAR SIGNALLING
- Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
- (2015) J. R. Brown et al. CLINICAL CANCER RESEARCH
- Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
- (2015) R. D. Morin et al. CLINICAL CANCER RESEARCH
- Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma
- (2015) Sylvain Mareschal et al. GENES CHROMOSOMES & CANCER
- Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
- (2015) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study
- (2015) Grzegorz S. Nowakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- The G protein–coupled receptor P2RY8 and follicular dendritic cells promote germinal center confinement of B cells, whereas S1PR3 can contribute to their dissemination
- (2015) Jagan R. Muppidi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
- (2015) Beata Holkova et al. LEUKEMIA & LYMPHOMA
- A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma
- (2015) John D. Hainsworth et al. LEUKEMIA & LYMPHOMA
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis
- (2015) Jiyuan Zhang et al. NATURE MEDICINE
- The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development
- (2015) Ana Ortega-Molina et al. NATURE MEDICINE
- High prevalence of theMYD88mutation in testicular lymphoma: Immunohistochemical and genetic analyses
- (2015) Naoki Oishi et al. PATHOLOGY INTERNATIONAL
- MYC Alterations in Diffuse Large B-Cell Lymphomas
- (2015) Kennosuke Karube et al. SEMINARS IN HEMATOLOGY
- B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma
- (2015) Ryan M. Young et al. SEMINARS IN HEMATOLOGY
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
- (2014) Tatyana Feldman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
- (2014) David J. Straus et al. BRITISH JOURNAL OF HAEMATOLOGY
- The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection
- (2014) L. Arcaini et al. HAEMATOLOGICA
- Consequences of the recurrentMYD88L265Psomatic mutation for B cell tolerance
- (2014) James Q. Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
- (2014) Anas Younes et al. LANCET ONCOLOGY
- Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
- (2014) Umberto Vitolo et al. LANCET ONCOLOGY
- A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma
- (2014) Craig C. Hofmeister et al. LEUKEMIA & LYMPHOMA
- Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma
- (2014) Jagan R. Muppidi et al. NATURE
- Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation
- (2014) A A Sahasrabuddhe et al. ONCOGENE
- High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type
- (2014) Anne Pham-Ledard et al. JAMA Dermatology
- Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
- (2013) F. Hitz et al. ANNALS OF HEMATOLOGY
- MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
- (2013) Z. Y. Xu-Monette et al. BLOOD
- Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program
- (2013) Y. Li et al. BLOOD
- A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
- (2013) Lihua E. Budde et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas
- (2013) Andrew M. Evens et al. BRITISH JOURNAL OF HAEMATOLOGY
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
- (2013) Y. Oki et al. CLINICAL CANCER RESEARCH
- Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma
- (2013) Elodie Bohers et al. GENES CHROMOSOMES & CANCER
- Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
- (2013) A. Chiappella et al. HAEMATOLOGICA
- Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
- (2013) Marieta Caganova et al. JOURNAL OF CLINICAL INVESTIGATION
- High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma
- (2013) W Kraan et al. LEUKEMIA
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
- (2013) M Wang et al. LEUKEMIA
- Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma
- (2013) Anne Pham-Ledard et al. MODERN PATHOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma
- (2013) Carol Y Ying et al. NATURE IMMUNOLOGY
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting pathological B cell receptor signalling in lymphoid malignancies
- (2013) Ryan M. Young et al. NATURE REVIEWS DRUG DISCOVERY
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
- (2013) M. Pfeifer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Hybrid Mechanism of Action for BCL6 in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoters
- (2013) Katerina Hatzi et al. Cell Reports
- Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies
- (2012) Z. Y. Xu-Monette et al. BLOOD
- Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
- (2012) Z. Y. Xu-Monette et al. BLOOD
- MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
- (2012) W. Cuccuini et al. BLOOD
- Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
- (2012) Ling-Hua Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma
- (2012) Stefano Monti et al. CANCER CELL
- Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL
- (2012) Daniel Nagel et al. CANCER CELL
- Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
- (2012) C. Visco et al. HAEMATOLOGICA
- Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
- (2012) J. A. Barnes et al. HAEMATOLOGICA
- Pathogenesis of follicular lymphoma
- (2012) Robert Kridel et al. JOURNAL OF CLINICAL INVESTIGATION
- MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- (2012) Anne Pham-Ledard et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- P53 deletion is independently associated with increased age and decreased survival in a cohort of Chinese patients with diffuse large B-cell lymphoma
- (2012) Zhuxia Jia et al. LEUKEMIA & LYMPHOMA
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
- (2012) J. G. Lohr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma
- (2011) Manuel Montesinos-Rongen et al. ACTA NEUROPATHOLOGICA
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
- (2011) G. Gutierrez-Garcia et al. BLOOD
- Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP
- (2011) Monica Testoni et al. BRITISH JOURNAL OF HAEMATOLOGY
- Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
- (2011) Francisco J. Hernandez-Ilizaliturri et al. CANCER
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
- (2011) Madhavi Challa-Malladi et al. CANCER CELL
- Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl
- (2011) G Monaco et al. CELL DEATH AND DIFFERENTIATION
- Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
- (2011) Pier Luigi Zinzani et al. Clinical Lymphoma Myeloma & Leukemia
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
- (2011) D. Chen et al. CURRENT CANCER DRUG TARGETS
- Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
- (2011) G S Nowakowski et al. LEUKEMIA
- BCL2 mutations in diffuse large B-cell lymphoma
- (2011) J M Schuetz et al. LEUKEMIA
- Inactivating mutations of acetyltransferase genes in B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas
- (2011) Shanshan Duan et al. NATURE
- Analysis of the coding genome of diffuse large B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE GENETICS
- The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinement
- (2011) Jesse A Green et al. NATURE IMMUNOLOGY
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2011) J. W. Friedberg Hematology-American Society of Hematology Education Program
- Oncogenic CARD11 Mutations Induce Hyperactive Signaling by Disrupting Autoinhibition by the PKC-Responsive Inhibitory Domain
- (2010) Rebecca L. Lamason et al. BIOCHEMISTRY
- EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
- (2010) I. Velichutina et al. BLOOD
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study
- (2010) F. Jardin et al. BLOOD
- Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma
- (2010) Richard R. Furman et al. CANCER
- Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma
- (2010) Dinis Pedro Calado et al. CANCER CELL
- BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell Lymphoma
- (2010) Jonathan Mandelbaum et al. CANCER CELL
- Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma
- (2010) C. J. Stasik et al. HAEMATOLOGICA
- Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium
- (2010) Sonali M. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
- (2010) Sharon Barrans et al. JOURNAL OF CLINICAL ONCOLOGY
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
- (2010) Jia Ruan et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
- (2009) K. Dunleavy et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma
- (2009) Suk-young Lee et al. CANCER SCIENCE
- BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome
- (2009) Maria Grazia Tibiletti et al. HUMAN PATHOLOGY
- Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations
- (2009) N Niitsu et al. LEUKEMIA
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
- BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma
- (2009) M. Saito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
- (2008) M. Crump et al. ANNALS OF ONCOLOGY
- Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
- (2008) K. H. Young et al. BLOOD
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
- (2008) W Klapper et al. LEUKEMIA
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
- (2008) G. Lenz et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation